Thursday, June 20, 2013

Improving from 20/400 to 20/40

Midwest Lens reports that “Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today confirmed that the vision of a patient enrolled in a clinical investigation of the company’s retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) has improved from 20/400 to 20/40 following treatment. The improvement was first reported on May 15, 2013, in a news article published by Reuters.” Read more.

No comments:

Post a Comment